Related Experiment Video
Updated: May 1, 2026

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
Published on: April 13, 2015
Interleukin-8 and interleukin-17 for cancer
Paul Zarogoulidis1, Fotini Katsikogianni, Theodora Tsiouda
1Department of Pulmonary, Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;
Pro-inflammatory cytokines, including interleukin-8 (IL-8) and interleukin-17 (IL-17), are linked to chronic inflammation and cancer progression. Inhibiting these cytokines may offer new treatments for inflammatory diseases and tumors.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Pro-inflammatory cytokines are implicated in chronic inflammation and inflammatory diseases.
- Elevated interleukin (IL) levels correlate with disease exacerbation and poor prognosis in various cancers.
- Cytokine-induced tumorigenesis is observed, exemplified by hepatitis-induced hepatocellular carcinoma.
Purpose of the Study:
- To review the role of Interleukin-8 (IL-8) and Interleukin-17 (IL-17) in disease pathogenesis.
- To explore their mechanisms in promoting neo-angiogenesis and metastasis.
- To discuss potential therapeutic strategies targeting cytokine production.
Main Methods:
- Literature review focusing on IL-8 and IL-17.
- Analysis of cytokine-induced pathways including VEGF, MMP-2, and MMP-9.
- Examination of therapeutic implications of cytokine inhibition.
Main Results:
- IL-8 and IL-17 induce neo-angiogenesis via vascular endothelial growth factor (VEGF) pathway activation.
- These interleukins enhance matrix metalloproteinase-2 and -9 (MMP-2, -9) activity, promoting cancer metastasis.
- Cytokine production inhibition presents a potential therapeutic avenue for inflammatory diseases and cancer.
Conclusions:
- IL-8 and IL-17 are key mediators in chronic inflammation and cancer progression.
- Targeting these cytokines offers a promising strategy for disease treatment and tumor modulation.
- Local immune modulation post-surgery, such as in lung cancer, may enhance anti-tumor immunity.
More Related Videos
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
Related Concept Videos
Tumor Immunotherapy
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
The Tumor Microenvironment